CRP and ovarian carcinoma: In ovarian cancer patients, both mAbs have shown good tolerability profiles and effective IL-6/IL-6R blockade, characterised by decreased serum C-reactive protein (CRP) and STAT3 activation and increased serum IL-6 and soluble IL-6R [8–10].